Biohaven (NYSE:BHVN) Shares Gap Up – Here’s Why

Biohaven Ltd. (NYSE:BHVN)’s share price gapped up prior to trading on Thursday. The stock had previously closed at $11.75, but opened at $16.10. Biohaven shares last traded at $15.1390, with a volume of 16,433,777 shares changing hands.

Key Headlines Impacting Biohaven

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: FDA review removes a key regulatory hurdle. The FDA accepted Biohaven’s resubmitted application, meaning the agency will conduct a formal review of Vyglxia. A regulatory decision is expected in the first quarter of 2027. Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
• Positive Sentiment: Investors are reassessing the drug’s commercial potential. Coverage highlighted the possibility that approval could give Biohaven a significant new growth opportunity in a rare neurological disease, helping explain the stock’s unusually large advance and some analyst price-target increases. Biohaven Soars 25% on FDA Drug Review, Price Target Upgrade
• Positive Sentiment: Trading activity reinforced the bullish move. Investors purchased 6,072 BHVN call options, approximately 155% above typical daily call volume, signaling heightened speculative interest in further upside. Why Biohaven catapulted 30%-plus and why it might not be done sprinting
• Neutral Sentiment: The FDA has accepted the application for review—not approved Vyglxia. The upcoming review creates a major catalyst, but the outcome remains uncertain and the company still faces the time and expense of completing the regulatory process. Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission
• Negative Sentiment: Sharp gains increase volatility and profit-taking risk. The stock’s rally appears driven largely by a single regulatory event and options activity, while Biohaven remains an unprofitable biotech. Any negative FDA feedback, delay, or questions about Vyglxia’s efficacy or market opportunity could reverse the move.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BHVN shares. Robert W. Baird set a $48.00 target price on shares of Biohaven in a research note on Thursday. Canaccord Genuity Group set a $21.00 price target on shares of Biohaven in a research note on Friday, August 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Biohaven in a report on Friday, June 26th. Morgan Stanley lifted their price objective on shares of Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Citigroup reissued a “buy” rating on shares of Biohaven in a report on Friday, September 18th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.25.

Biohaven Trading Down 5.5%

The stock’s 50-day simple moving average is $13.51 and its two-hundred day simple moving average is $12.70. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73. The firm has a market capitalization of $2.10 billion, a P/E ratio of -2.99 and a beta of 1.35.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). Equities research analysts expect that Biohaven Ltd. will post -3.33 EPS for the current year.

Hedge Funds Weigh In On Biohaven

A number of institutional investors and hedge funds have recently modified their holdings of BHVN. BlueCrest Capital Management Ltd bought a new stake in shares of Biohaven in the 2nd quarter worth about $60,000. Sterling Capital Management LLC raised its position in Biohaven by 847.5% in the 3rd quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock worth $59,000 after purchasing an additional 3,975 shares during the last quarter. IFP Advisors Inc lifted its holdings in Biohaven by 43.3% during the 2nd quarter. IFP Advisors Inc now owns 6,011 shares of the company’s stock worth $89,000 after buying an additional 1,816 shares in the last quarter. Allworth Financial LP bought a new position in Biohaven in the 2nd quarter valued at $117,000. Finally, Essential Partners LLC increased its stake in shares of Biohaven by 31.7% in the 1st quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock valued at $76,000 after buying an additional 2,169 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.